The ultimate goal of our dedicated team of employees is to advance research for treatments of serious and life-threatening infections.

At the time of our company’s founding in 2005, we focused our energy on advancing our lead product candidate‚ ceftaroline fosamil. In 2007, we became a wholly-owned subsidiary of Forest Laboratories. The collaboration between Cerexa and Forest allows us to integrate and capitalize on our collective resources.

Ceftaroline is a novel, bactericidal‚ broad-spectrum‚ injectable cephalosporin antibiotic in development for the treatment of resistant gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP), as well as common gram-negative organisms. We recently completed Phase III studies of ceftaroline for the treatment of complicated skin and skin structure infections (cSSSI). Phase III studies for the treatment of community- acquired pneumonia (CAP) are underway.

We are also developing a novel intravenous beta-lactamase inhibitor, NXL104, to be used in combination with ceftaroline. Beta-lactamase inhibition represents a mechanism for counteracting resistance and enhancing broad-spectrum activity of beta-lactam antibiotics. Microbiology studies of NXL104 in combination with ceftaroline demonstrated that NXL104 increases ceftaroline’s activity against beta-lactamase-producing gram-negative pathogens. We plan to initiate Phase I studies of the ceftaroline/NXL104 combination in 2009.

We conduct our business with the highest ethical standards. We believe that our ability to positively impact people’s health and save lives is directly linked with the quality of our employees and our research and development activities.